AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Rhea-AI Summary

AbbVie (NYSE: ABBV) will invest $380 million to build two new active pharmaceutical ingredient (API) facilities at its North Chicago campus, supporting next-generation neuroscience and obesity medicines. Construction starts spring 2026 and both facilities are expected to be fully operational in 2029.

The project will add advanced manufacturing and AI integration and is expected to create 300 jobs in engineering, science and operations, and is part of AbbVie's broader $100 billion U.S. R&D and capital commitment over the next decade.

Positive

• $380M capital investment announced for U.S. API manufacturing
• Plans to hire 300 workers in North Chicago
• Facilities to integrate advanced manufacturing and AI for next-gen drugs
• Supports reshoring of API production from Europe and Asia
• Part of AbbVie's $100B U.S. R&D and capital commitment

Negative

• Facilities not expected to be fully operational until 2029, a long lead time

News Market Reaction – ABBV

+2.08%

1 alert

+2.08% News Effect

On the day this news was published, ABBV gained 2.08%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

North Chicago investment: $380 million U.S. investment commitment: $100 billion New facilities: 2 facilities +5 more

8 metrics

North Chicago investment $380 million New API manufacturing facilities at existing campus

U.S. investment commitment $100 billion Planned R&D and capital investments over the next decade

New facilities 2 facilities New API manufacturing buildings in North Chicago

New hires 300 people Planned staffing for new North Chicago facilities

U.S. workforce 29,000 employees AbbVie employment across all 50 states and Puerto Rico

U.S. manufacturing staff 6,000 employees Headcount at U.S. manufacturing sites

Illinois employment 11,500 employees AbbVie workforce in Illinois, including headquarters

Operational date 2029 Expected year both new facilities become fully operational

Market Reality Check

Price: $232.16 Vol: Volume 4,236,380 is 0.58x...

low vol

$232.16 Last Close

Volume Volume 4,236,380 is 0.58x its 20-day average of 7,323,112, indicating subdued trading interest ahead of this announcement. low

Technical Shares at 225 are trading above the 200-day moving average of 211.26, reflecting a pre-existing upward trend into this capex news.

Peers on Argus

ABBV’s modest 0.21% gain contrasts with mixed peer action: LLY appeared in momen...

1 Up 1 Down

ABBV’s modest 0.21% gain contrasts with mixed peer action: LLY appeared in momentum scanners with a 4.25% move up, while NVO showed a -15.78% move down. This pattern points to stock-specific drivers rather than a broad pharma rotation.

Historical Context

5 past events · Latest: Feb 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 20	FDA approval	Positive	-0.2%	FDA approved VENCLEXTA plus acalabrutinib for previously untreated CLL.
Feb 19	Dividend declaration	Positive	-1.9%	Declared quarterly cash dividend of $1.73 per share for shareholders.
Feb 04	Earnings results	Positive	-3.8%	Reported 2025 revenues of $61.160B with detailed EPS and 2026 guidance.
Feb 03	Aesthetics program	Neutral	+0.0%	Launched Faces of Natrelle testimonial program for U.S. augmentation patients.
Feb 03	Regulatory filings	Positive	+0.0%	Submitted FDA and EMA applications for RINVOQ in adults and adolescents with vitiligo.

Pattern Detected

Recent history shows several positive catalysts (FDA approval, dividend, earnings, regulatory filing) followed by flat to negative next-day moves, suggesting the stock has often traded weakly around good news.

Recent Company History

Over the past month, AbbVie has reported multiple significant updates. On Feb 20, it received FDA approval for a VENCLEXTA plus acalabrutinib regimen in first-line CLL. A day earlier, on Feb 19, it declared a quarterly dividend of $1.73 per share. On Feb 4, AbbVie posted full-year 2025 revenues of $61.160B and issued 2026 EPS guidance of $14.37–$14.57. Additional February news covered aesthetics marketing and new RINVOQ vitiligo filings. Today’s manufacturing investment fits into this pattern of ongoing strategic expansion.

Market Pulse Summary

This announcement highlights AbbVie’s plan to invest $380 million in two new API facilities, contrib...

Analysis

This announcement highlights AbbVie’s plan to invest $380 million in two new API facilities, contributing to a broader $100 billion U.S. R&D and capital program over the next decade. The facilities aim to support next-generation neuroscience and obesity medicines and are expected to be fully operational in 2029, adding about 300 jobs. In context of recent FDA approvals, dividend growth, and robust 2025 revenues, investors may watch how this manufacturing build-out supports future product launches and supply reliability.

Key Terms

active pharmaceutical ingredient, api, artificial intelligence, ai, +1 more

5 terms

active pharmaceutical ingredient medical

"two new active pharmaceutical ingredient (API) manufacturing facilities"

The active pharmaceutical ingredient (API) is the chemical or biological substance in a medicine that produces the intended therapeutic effect, separate from inactive ingredients like fillers, binders or coatings. Investors watch APIs closely because their source, patent status, manufacturing cost, quality controls and supply reliability drive a drug’s safety, regulatory approval, margin and commercial potential—like the engine in a car determining performance and value.

api medical

"two new active pharmaceutical ingredient (API) manufacturing facilities"

An API, or Application Programming Interface, is a set of rules that allows different software programs to communicate and work together smoothly, much like a waiter translating your order into the kitchen and then bringing your meal back. For investors, APIs are important because they enable real-time access to financial data, trading systems, and other digital services, making it easier to make informed decisions quickly and efficiently.

artificial intelligence technical

"integrate advanced manufacturing technologies with artificial intelligence (AI)"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

ai technical

"integrate advanced manufacturing technologies with artificial intelligence (AI)"

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

chemical synthesis technical

"the first phase of this investment, a new chemical synthesis facility"

Chemical synthesis is the laboratory or industrial process of creating specific molecules by combining and transforming simpler chemical building blocks, like following a recipe to bake a cake but for chemicals. It matters to investors because how easily and cheaply a substance can be synthesized affects production costs, supply reliability, patent strength and regulatory approval, all of which influence a company’s ability to make and sell chemical or pharmaceutical products profitably.

AI-generated analysis. Not financial advice.

• Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade
• Two new facilities will be built to add advanced manufacturing capabilities to support the production of next-generation neuroscience and obesity medicines
• Construction will begin in spring 2026, with the site fully operational in 2029

NORTH CHICAGO, Ill., Feb. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.

Construction will begin in spring 2026, with both new facilities expected to be fully operational in 2029. To support these new facilities, AbbVie plans to hire 300 people in North Chicago, including engineers, scientists, manufacturing operators and lab technicians.

"This milestone demonstrates further progress against our $100 billion commitment to U.S. R&D and capital investments over the next decade," said Robert A. Michael, chairman and chief executive officer, AbbVie. "By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients."

Active pharmaceutical ingredient manufacturing is a complex, multi-step process that involves producing the active components responsible for a medication's therapeutic effects. Over the past six months, AbbVie has announced plans to significantly expand its API manufacturing capabilities and capacity in the U.S. In September 2025, AbbVie broke ground on the first phase of this investment, a new chemical synthesis facility that will enable the return of API production for select neuroscience, immunology and oncology products from Europe and Asia to the U.S.

With a presence in all 50 states and Puerto Rico, AbbVie employs approximately 29,000 people in the U.S., including more than 6,000 at its U.S. manufacturing sites. This investment helps to advance AbbVie's long-term commitment to Illinois, where it is headquartered and employs more than 11,500 people.

In addition to its planned investments in Illinois, AbbVie recently announced plans to acquire a device manufacturing facility in Arizona and to make significant investments at its manufacturing facility in Massachusetts. AbbVie is currently in discussions with multiple U.S. states about potential manufacturing investments and anticipates announcing additional investments in 2026.

About AbbVie 

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements  

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

Media: John Torrisi    (224) 213-0055 john.torrisi@abbvie.com

Investors: Liz Shea (847) 935-2211 liz.shea@abbvie.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-to-invest-380-million-in-north-chicago-to-further-expand-active-pharmaceutical-ingredient-manufacturing-in-the-united-states-302694659.html

SOURCE AbbVie

FAQ

What did AbbVie (ABBV) announce on February 23, 2026 about North Chicago?

AbbVie announced a $380 million investment to build two API facilities at North Chicago, starting spring 2026. According to the company, construction will begin in spring 2026 and both facilities are expected to be fully operational in 2029.

How many jobs will AbbVie's (ABBV) North Chicago expansion create and what roles?

AbbVie plans to hire 300 people in North Chicago, including engineers and scientists. According to the company, roles include manufacturing operators and lab technicians to support API production for neuroscience and obesity medicines.

What medicines will the new AbbVie (ABBV) API facilities support and why?

The new facilities will support next-generation neuroscience and obesity medicines by producing active pharmaceutical ingredients. According to the company, they will integrate advanced manufacturing and AI to enhance production capabilities.

When will AbbVie's (ABBV) North Chicago API facilities be completed and operational?

Construction is scheduled to begin in spring 2026, with both facilities expected to be fully operational in 2029. According to the company, the multi-year build reflects complex API manufacturing and advanced technology integration.

How does the $380 million North Chicago investment fit into AbbVie's (ABBV) U.S. strategy?

This investment is part of AbbVie's $100 billion U.S. R&D and capital commitment over the next decade. According to the company, the project strengthens U.S. manufacturing and supports reshoring API production for key therapeutic areas.